These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 34411840)

  • 1. Antiphospholipid syndrome-induced ischemic stroke following pembrolizumab: Case report and systematic review.
    Tota V; Dagonnier M; Wery D; Binet L; Nagy N; Durieux V; Diaz M; Elosegi JA; Holbrechts S
    Lung Cancer; 2021 Oct; 160():59-65. PubMed ID: 34411840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delayed immune-related neutropenia with hepatitis by pembrolizumab.
    Nakako S; Nakashima Y; Okamura H; Tani Y; Ueda T; Makuuchi Y; Kuno M; Takakuwa T; Nishimoto M; Koh H; Nakamae H; Hino M
    Immunotherapy; 2022 Feb; 14(2):101-105. PubMed ID: 34758635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.
    Naqash AR; Appah E; Yang LV; Muzaffar M; Marie MA; Mccallen JD; Macherla S; Liles D; Walker PR
    J Immunother Cancer; 2019 Jul; 7(1):169. PubMed ID: 31277704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dramatic, significant metabolic response to a one-time pembrolizumab treatment following a relapse of pre-existing organizing pneumonia in a patient with advanced non-small cell lung cancer: A case report.
    Kato M; Mori M; Miura K; Asao T; Motomura H; Nishino K; Ko R; Koyama R; Hayashi T; Takahashi K
    Thorac Cancer; 2021 Nov; 12(22):3076-3079. PubMed ID: 34617405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases.
    Zhang M; Rodrigues AJ; Pollom EL; Gibbs IC; Soltys SG; Hancock SL; Neal JW; Padda SK; Ramchandran KJ; Wakelee HA; Chang SD; Lim M; Hayden Gephart M; Li G
    J Neurooncol; 2021 Mar; 152(1):125-134. PubMed ID: 33415659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compromise or not? A case report of successful treatment of pembrolizumab-induced hepatitis in a patient with non-small cell lung cancer with low-dose methylprednisolone and bicyclol.
    Liu Y; Zhang J; Yin Z; Zhu X; Xue L; Cao B
    Thorac Cancer; 2020 Jul; 11(7):2023-2030. PubMed ID: 32379397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer.
    Komiya K; Nakamura T; Abe T; Ogusu S; Nakashima C; Takahashi K; Kimura S; Sueoka-Aragane N
    Thorac Cancer; 2019 Sep; 10(9):1798-1804. PubMed ID: 31328416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
    Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
    Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes.
    Cortellini A; Friedlaender A; Banna GL; Porzio G; Bersanelli M; Cappuzzo F; Aerts JGJV; Giusti R; Bria E; Cortinovis D; Grossi F; Migliorino MR; Galetta D; Passiglia F; Berardi R; Mazzoni F; Di Noia V; Signorelli D; Tuzi A; Gelibter A; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Inno A; Di Marino P; Mansueto G; Zoratto F; Santoni M; Tudini M; Ghidini M; Filetti M; Catino A; Pizzutilo P; Sala L; Occhipinti MA; Citarella F; Russano M; Torniai M; Cantini L; Follador A; Sforza V; Nigro O; Ferrara MG; D'Argento E; Leonetti A; Pettoruti L; Antonuzzo L; Scodes S; Landi L; Guaitoli G; Baldessari C; Bertolini F; Della Gravara L; Dal Bello MG; Belderbos RA; De Filippis M; Cecchi C; Ricciardi S; Donisi C; De Toma A; Proto C; Addeo A; Cantale O; Ricciuti B; Genova C; Morabito A; Santini D; Ficorella C; Cannita K
    Clin Lung Cancer; 2020 Nov; 21(6):498-508.e2. PubMed ID: 32680806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab-induced hypothyroidism caused reversible increased serum creatinine levels: a case report.
    Matsuoka N; Tsuji K; Ichihara E; Hara T; Fukushima K; Toma K; Kitamura S; Inagaki K; Sugiyama H; Wada J
    BMC Nephrol; 2020 Mar; 21(1):113. PubMed ID: 32234009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe Thrombocytopenia Associated With Pembrolizumab in Patients With Non-small Cell Lung Cancer (NSCLC): A Case Report and Literature Review.
    Mouri A; Kaira K; Shiono A; Miura YU; Kagamu H
    In Vivo; 2020; 34(2):877-880. PubMed ID: 32111798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
    Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
    Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal Effects after Pembrolizumab Treatment for Non-small Cell Lung Carcinoma.
    Oki R; Hirakawa Y; Kimura H; Honda K; Hinata M; Abe H; Domoto Y; Tanaka G; Nagase T; Nangaku M
    Intern Med; 2020 Apr; 59(7):977-981. PubMed ID: 31813918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Immune-Related Adverse Events and Efficacy Outcomes With Consolidation Pembrolizumab After Chemoradiation in Patients With Inoperable Stage III Non-Small-Cell Lung Cancer.
    Shukla NA; Althouse S; Meyer Z; Hanna N; Durm G
    Clin Lung Cancer; 2021 Jul; 22(4):274-281. PubMed ID: 33610454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case report: reinitiating pembrolizumab treatment after small bowel perforation.
    Beck TN; Kudinov AE; Dulaimi E; Boumber Y
    BMC Cancer; 2019 Apr; 19(1):379. PubMed ID: 31018834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
    Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
    JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Steroid-refractory dermatologic and pulmonary toxicity in a patient on rituximab treated with pembrolizumab for progressive urothelial carcinoma: a case report.
    Hines J; Daily E; Pham AK; Shea CR; Nadeem U; Husain AN; Stadler WM; Reid P
    J Med Case Rep; 2021 Mar; 15(1):124. PubMed ID: 33736690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety and efficacy of pembrolizumab for the treatment of non-small cell lung cancer.
    Mazarico Gallego JM; Herrera Juárez M; Paz-Ares L
    Expert Opin Drug Saf; 2020 Mar; 19(3):233-242. PubMed ID: 32129104
    [No Abstract]   [Full Text] [Related]  

  • 20. Pembrolizumab-induced thrombotic thrombocytopenic purpura.
    Dickey MS; Raina AJ; Gilbar PJ; Wisniowski BL; Collins JT; Karki B; Nguyen AD
    J Oncol Pharm Pract; 2020 Jul; 26(5):1237-1240. PubMed ID: 31718453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.